ABSTRACT: Reports of negative trials arc mcreasmg in number as ~tandard therapy tor many gastrointestinal diseases is refineJ. The validity of a negative report Jepcnds on •he number of patients in the trial, the alpha and bern error and the difference in ethcacy which the trial is able to detect. The relationship between these parameters ,,discussed rt.id a formula given for the calculation of trial size. All reports of negatll'l trials should include not only the number of patients involvt:d and the level of s1gmficance of the results but abo the beta error and the detectable difference in ett1cacy of thl' treatments. Can J Gastrocnterol 1988;2( 4 ): 14 7-50
T HH \tl'H:\ <;J", l:S. THl 1, TRl )I)\ ( Tll)S.:
of many new medications (l)r dw 1rr,11mcn1 of ga,1rom tl·,1 ma I d1~orders ts 011h.11 che new drug 1s 1hcrapeuncally ,llpl'nor to the old but I hat 11 1s a~ effl'l'-01, ,h the old If the rwwcr medrcauon ha, an .iJvancage over , tandard treat ment, such as a more acceptable dosage r~c1men (lr fc\\'er ,1de effect,, then pre1umablv it is to be preferred A, a wn,eq uence of ch is we n re pre-,c111rJ ll'Hh trial, 1ha1 appe,ir to show no difference between t reatments So calkJ ·ncgati\'c· tri,11' ha,·l' pl·cul1:1r ,it1hodol11g1,al prohkms "hich 11 1, imp1>rtanc co ,1ppreci:lll'. The nw,1 1m-pt1rt.1nt limitation o( these mab b thac it 1', rrtu.dly 1mpo,,1bk tn ensure ..:omparahk dfiLac,· Negative trials may. li! ..:our~L', he, en useful hut they may .11,o bl' dl'trtnwntal 1! thl'y rl'sul1 in the acn'pcance of lll'\\'l'r ml'dicnl!(ins which .ll'l' no t a, dtcctive ,1' s1,111dard treatment or if they delay the rntn>duLtinn nf usdul thcrap, The ,,urpmc 
NORMAL DISTRIBUTION
Thl' normal d1,1r1hu1t()n 1, re.illy ,1 pruhahilit\ distnbutron . It is ,ymml'tm ,rnd hL'll-sh aped ( Figure I ). Thi;. tvpc ol dhtrtht1tH1n 1s common tor factor, 1,·h1ch shnw l'ariahilit\ and arc continuoLh Thl' d1strihucit1n rs described hy rt~ mean and the lkv1a11on nt value, Imm the mean. It', tlw st,rndard dt,,·ia1ion The ,1rca under the Lllr\'l' ts 100''., and corre~ponds 10 a prnbahiln, uf I Roughly l)5",, of, al lll'' lie w1thm I he arl' a ddincd hv thl' mcnn ± 2 standard de, 1atrons from the llk'an Thl' ilrl'a x ,n each 1atl of I 1gurc I ts 2 1''., nf the' tot,11 nren and corresponds, thnet1,rc. 10 a probabilrty of Figure 3 . We obtain a sample of British males as before. By chance, the mean of the sample now foils sufficemly close to the mean of the Canadian males for us to say that there is no difference between the AST values of Canadians and those of the British. The populations, however. really arc different. We h:we t'xtrnpolated hack fn>m our sample of British males t1> cc111eludc that rlwrc is 110 difference hctwt•en the populations when therL' actually is a difference. This is a beta error. Bera l'rrnr occur, when no difference between the populations heing studied is claimed hut a difference actually exists This type of error is especially important in 'negat1\'e' trials, ie. tna ls in which no difference is claimed. Th,s 1s more easily ~el'n by wny of an ex;imple. If we obtained a sample of populatitm B whose mean fell at point X we \\'ould conclude chnt population A and population B were identical. We wou ld conclude thi:; because the mean of rhe sample I which is being used to estimate the mean of population B) foils sufficiently close ro the mean of population A for u:; to say that there is no statistical difference between populations A and B Since these population:-. are actually different chis is a heta error.
As might be expected from 
DETERMINANTS OF T RIAL SIZE
Effect of increasing the number of s ubj ects ( n ): Intuitively we can rcco~-ni:e that increasing the sample size will increase che likelihood of the ,nmplc accurately refleccin).! the populat1<>n \\'hich we w1,h to study Increasing the number of p.:itients 1n n trial abo tightern, thL' srnndard error or spread of rhc ~ample and lwnce wil l l1l't'l'L''1~L' tht· n,k of error. In addition. incre.ising trial si:c increases the power of many ~cau~tical tescs. Small tmds are part icularly pn>nc to hern t'rror ,incl' the spread of the sam-CAN J GAS I ROENHROL li\'C colins Wt're exceedi ngly rare then clcnrly the numhcr o f patients requi red in a trial \\"ould be a ffected.
CALCULATION OF SIZE FOR NEGATIVE TRIALS
Any formula fo r calcu lminn of trial size must incorporate a lp h ;i error. bcm error the di fference he1,,·ec'n treatments that 1, t() he detected ,md 1hc frc·qucn cy ()f the studied C\'ent.
There ,1rc manv ditferc'n l matht·mati - 
Methodology of negative trrols
From Tnble I the function f(alpha.bera) eq ua b 10.5 Let us also accept thm 5-ASA will still h e a useful t reatment ifit is 10''., less effccuve than sulfasa lnine thl'n d -10 P uttin g t h ese values inw the equation:
11 2 )( 9l) X ( report of a difference between treatments 1f informatton was n ot gi"en on the result:-. of s1gnrficance testing. Why should we accept reports o f no difference bc·-tween treatments unless the correspon ding beta e r ror is gi\'en 1 TRIAL DESIGN Trial d esign represen ts a balance hetween the statistical rcquircml'nts ( which tend to in crease patien t nu m hers ) ,md clinical p racucality ( which tends to m111 -im1zc patient number, ). When designing tr1als we cannot change tlw k,·el of alpha error. The beta error may be varied ,omewha t but b nm a cnrical dcrerminant of ,i:e. The re,ponse ro stan<larJ rrearment is a biological fact The on ly parameter wh ich 1s variable and n major determinate of st:e is the difference between llTatment,. This difference has a ma1or effect on trial si:e since the number of p,1ue1w, required is apprllx 1mately inversely proport1(1nal to the square o f thL' difference l the smaller the difference the greater the n umher ol patiL·nt, n:quircJ) Cc)Jlsciou~ly in designed triab. or unconsci<>usly 111 prn,rly designed trials. this ts rhe parameter that is ;1ltered .
There 1s nmhing wron)l wnh a sm;11l v1..:wed with caution 1f informatio n 1s 11l> t given on rhc size of thl' beta error anJ the dewcrnhle difference between trL'at· men ts. All tnab should report both th~ alpha and beta level mcorporatcd tnto the trial. This is especially importnnr for rria ls for which no difference is hetng claimed. It will then be f(>r the reader w decide if the trial b truly 'ncgati,·e·. 
